Publication:
Contemporary validation of the renal cell carcinoma inflammatory score (RISK) for preoperative prognostication in non-metastatic renal cell carcinoma

dc.contributor.coauthorBraunschweig, A.
dc.contributor.coauthorAgu, G. E.
dc.contributor.coauthorLahiji, R.
dc.contributor.coauthorPatil, D.
dc.contributor.coauthorSon, L. L.
dc.contributor.coauthorLuke, W.
dc.contributor.coauthorGoodstein, T. A.
dc.contributor.coauthorImtiaz, N.
dc.contributor.coauthorYildirim, A.
dc.contributor.coauthorMoulton, M.
dc.contributor.coauthorMumford, S.
dc.contributor.coauthorJoshi, S.
dc.contributor.coauthorGrajales, V.
dc.contributor.coauthorNarayan, V. M.
dc.contributor.coauthorNabavizadeh, R.
dc.contributor.coauthorHajiha, M.
dc.contributor.coauthorKhater, N.
dc.contributor.coauthorOgan, K.
dc.contributor.coauthorBilen, M. A.
dc.contributor.coauthorMaster, V. A.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorEsen, Barış
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2026-07-19T19:48:34Z
dc.date.issued2026
dc.description.abstractThe renal cell carcinoma (RCC) inflammatory score (RISK) is a preoperative prognostic model incorporating easily accessible inflammatory markers. This study validates the prognostic value of the RISK score and compares RCC prognostic models in a non-metastatic RCC cohort. METHODS: Following IRB approval, patients from Emory's Nephrectomy Database, undergoing nephrectomy for non-metastatic RCC between 2007-2024 were included. RISK scores were calculated using CRP, albumin, ESR, AST, ALT, and corrected calcium. Scores were classified as baseline (0), low (1-3), intermediate (4-6) and high (7-10) risk. Overall survival (OS) and Disease-Free survival (DFS) were analyzed using Cox proportional hazards models. Time-dependent AUC analyses compared RISK against Stage, Size, Grade and Necrosis (SSIGN), UCLA Integrated Staging System (UISS), and Mayo PFS models at 1-, 3-, 5-, and 10-years. RESULTS: 1056 patients were included. Increasing RISK categories were independently associated with worse DFS and OS. Compared with no/baseline-risk patients, high-risk patients had worse DFS (HR 3.38, 95% CI 1.82-6.29, p
dc.description.harvestedfromManual
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.versionPublished Version
dc.identifier.WoSQuartileN/A
dc.identifier.doi10.1097/upj.0000000000001040
dc.identifier.eissn2352-0787
dc.identifier.embargoN/A
dc.identifier.issn2352-0779
dc.identifier.pubmed42296303
dc.identifier.urihttp://doi.org/10.1097/upj.0000000000001040
dc.identifier.urihttps://hdl.handle.net/20.500.14288/33557
dc.keywordsMayo PFS
dc.keywordsPrognostication
dc.keywordsRisk score
dc.keywordsRenal cell carcinoma
dc.keywordsSurvival
dc.languageeng
dc.publisherWolters Kluwer Health
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofUrology Practice
dc.relation.openaccessN/A
dc.rightsN/A
dc.rights.uriN/A
dc.subjectHealth sciences
dc.subjectMedicine
dc.titleContemporary validation of the renal cell carcinoma inflammatory score (RISK) for preoperative prognostication in non-metastatic renal cell carcinoma
dc.typeJournal Article
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files